

Certificate of Attendance

presented to

M. Hidayat, MD

has attended as

Speaker



SCAN HERE

CELEBRATING
THE 34 ANNIVERSARY
of JEC

MARCH 10 - 11, 2018
Pullman Grand Ballroom
Pullman Hotel, Central Park
Jakarta, Indonesia

Johan A. Hutauruk, MD
President Director
JEC Corporate

Setiyo Budi Riyanto, MD
Chairman
JEC International Meeting 2018



4/12/2019

Bilateral Optic Neuritis: How to Diagnose and Manage the Disease

Muhammad Hidayat, MD

Abstract

Bilateral optic neuritis usually presents as **sudden onset of bilateral visual loss.**

Usually thought to affect children, often follows a viral syndrome, and is not typically associated with subsequent multiple sclerosis.

In adults simultaneous bilateral acute optic neuritis has been considered **rare** particularly in individuals **without known systemic inflammatory or autoimmune disorders.**

- Corticosteroid is still the first choice of treatment → showing an improvement but still unsatisfying
- Another combination of therapy probably needed based on the etiology and special circumstances.


Introduction


Optic neuritis (ON) : **inflammation of the optic nerve.**

Presented in isolation or associated with multiple sclerosis (MS) or occur in the setting of neuromyelitis optica (NMO).

Diagnosis: Typical and Atypical Optic Neuritis

- Triad :

 subacute unilateral loss of vision

 periocular pain

 impaired colour vision

- Mostly caused by idiopathic inflammatory demyelination → occur as an isolated syndrome or in association with **multiple sclerosis (MS)**.

Atypical features :

Absence of pain : 8% of people with typical ON

Marked swelling of the nerve, with retinal exudates and peripapillary hemorrhages

Evidence of neuroretinitis : macular star

Severe visual loss to no light perception,

Progression of visual loss or pain for more than 2 weeks

Bilateral Optic Neuritis


Bilateral acute optic neuritis in adults is related to multiple sclerosis (MS), about 10-75%



Morrissey et al. found bilateral acute optic neuritis in 23 adult and 5 patient (22%) with MS

- **Bradley dan Whitty** classified the patient to :
 - unilateral optic neuritis (71%)
 - bilateral simultaneous (7%)
 - bilateral neuritis and non simultaneous might present within 3 months.
- **No significant recovery time in bilateral or unilateral**

Bilateral Optic Neuritis



Ancillary Test

- | | |
|--|--|
| <ul style="list-style-type: none">• MRI• Computerized tomography (CT)• Cerebrospinal fluid examination to detect cells (in infective and atypical inflammatory causes), elevated protein, and oligoclonal bands.• Blood tests and other paraclinical investigations | <ul style="list-style-type: none">• Toxin screens, serum B12, mitochondrial genetics for Leber's hereditary optic neuropathy,• Orbital ultrasound for posterior scleritis• Optical coherence tomography• Fluorescein angiography, and electroretinography for retinal disease |
|--|--|

Management

The largest study for management of ON is the Optic Neuritis Treatment Trial, a multicenter randomized clinical trial with fifteen years of follow up.

Patients were assigned to three groups:

1. Received oral prednisone (1 mg/kg for 14 days),
2. Received intravenous methylprednisolone (250 mg iv 4 time a day for 3 days) followed by an oral prednisone taper (1 mg/kg for 11 days), and
3. Received oral placebo.

The trial showed that **intravenous corticosteroids followed by an oral taper accelerated visual recovery**, but did not improve the long-term visual outcome when compared to placebo.

ON associated with systemic autoimmune disease, vasculitis, or sarcoidosis

- The most common treatment option is to use highdose steroids at onset : 3–5 days of 1000 mg IV methylprednisolone
- In autoimmune disease :
 - The earlier steroids are started in lupus-associated ON, the better the visual outcome
 - Treatment of sarcoidosis refractory to steroids may include immunosuppressive agents (eg, azathioprine and cyclosporine) and antimetabolites (cyclophosphamide, chlorambucil, and methotrexate).

Special scenarios in the treatment of ON

- Special scenarios in the treatment of ON include pediatric ON and ON occurring during pregnancy

Pediatric ON

Treatments may include high-dose steroids, IV immunoglobulin, and TPE.

IV methylprednisolone is given on a weight-based regimen (4–30 mg/kg/day) up to 1 g for 3–5 days.

Difference between adults and pediatric ON

in a higher number of pediatric ON cases, there may be worsening if steroids are tapered too quickly

ON occurring during pregnancy

- In pregnancy, steroids are not contraindicated.
- Methylprednisolone is a pregnancy category C drug, but this risk is considered low, and IV methylprednisolone is generally regarded to be relatively safe for pregnancy.
- Patients were given 2 g/kg within the first 2 months of pregnancy, then 0.4 g/kg every 6 weeks until 12 weeks postpartum.

- Treatment for all patients are based on ONTT protocol

TABLE 1.2. Treatment recommendations of the Optic Neuritis Treatment Trial

- Corticosteroid treatment should be considered when the brain MRI scan reveals multiple abnormalities consistent with MS.
- Methylprednisolone 250 mg IV should be administered to patients with optic neuritis over a 30-min period every 6h for a total of 12 doses, or 1 g IV methylprednisolone in one dose over 1h each day for 3 consecutive days, followed by a prednisone taper at 1 mg/kg/day orally for 11 days. Prednisone should be tapered to 20mg on day 15 and to 10mg on days 16 and 18. There are no current studies to demonstrate a clinically significant difference between administering IV methylprednisolone four times a day and giving it all in one dose.
- IV methylprednisolone decreases the incidence of more neurological deficits within the 2 years after treatment, especially in patients who had initial abnormal brain MRI scans.
- IV methylprednisolone does not improve the ultimate visual outcome.

Study of Bilateral Optic Neuritis in dr. M. Djamil Hospital (2017)

- **Outward Patients with :**
 - Visual function testing : follow up of 3 days, 2 weeks, and 3 months.
 - Presence or absence of pain with extraocular movement.
 - Visual acuity
 - Perimetry
 - Neuro-imaging (CT Scan)

Patients were hospitalized

methylprednisolone 250 mg (iv)
every 6 hours/day for 3 days

Followed by oral prednisone
1mg/ kg/ day for 11 days

Followed by a gradual dose
reduction

Result

→ 9 patients had bilateral optic neuritis vision from January 2016 to January 2017

3 Men, 6 women → 21 - 45 years old

Orbital pain was found in all 9 patients

Visual acuity ranging from finger counting to hand movement, with sudden onset

RE : 1/300 to 3/60, with mostly 1/300 : 4 eyes (44%), 1/60 : 2 eyes (22%), 2/60 2 eyes (22%), 3/60 : 1 eye (11%)

LE : 1/300 to 5/60, mostly 1/60 : 2 eyes (22%), 4/60 and 5/60 : 1 eye (11%)

- All patients were treated with prednisolone IV 4x 250 mg in 3 days (total 12x)
 - Followed by oral prednisone 11 days : 1 mg/kg BB, and tapering off

Perimetry : mostly unspecific → central scotoma, quadrantanopia scotoma, general depressed, and multiple focal

CT scan within normal limit

No.	Age	Sex	Visual Acuity Before Treatment		Visual Acuity after 3 days treatments		Visual Acuity after 2 weeks treatments		Visual Acuity after 3 months treatments	
			RE	LE	RE	LE	RE	LE	RE	LE
1	30	P	3/60	5/60	6/9	1/60	6/7.5	6/9	6/6F	6/7.5
2	21	P	1/300	4/60	6/21	6/9	6/12	6/6	6/10	6/6
3	41	P	1/300	1/60	1/60	6/6 f	1/60	1/60	1/60	1/60
4	30	P	1/60	3/60	6/9	6/7.5	6/7.5	6/7.5	6/6	6/6
5	39	L	2/60	3/60	6/6 f	6/12	6/6 f	6/6 f	6/6	6/6
6	23	L	2/60	2/60	6/7.5	6/7.5	6/6	6/6	6/6	6/6
7	45	L	1/300	2/60	6/12	6/6 f	6/7.5	6/6	6/6	6/6
8	43	P	1/300	1/60	6/7.5	1/60	6/6f	6/6f	6/6	6/6
9	35	L	1/60	1/300	6/6 f	6/9	6/6	6/6f	6/6	6/6

Discussion

- Our study shows prevalence of bilateral optic neuritis in **female is more than male** with ratio 2:1. All literatures stated that female outnumbered male, thus, supporting our study.
- **Orbital pain was found in all patients.** In the literature stated that pain within and around the affected eye arises before or at the time of the onset of visual loss in about 90% of cases.
- **Sudden visual loss in both eyes** is the chief complain from all patients in this study, suitable to the main sign of optic neuritis.

- Visual outcome in 8 patients are good, with 20/20 after 2 weeks follow up.
- **Visual outcome for bilateral optic neuritis is better after treatment of IV methylprednisolone and oral prednisone,** reaching up to 20/20 in 6 months to 1 year of follow up. The benefit of this treatment regiments is greatest in the first 15 days.
- The remaining 1 patient in this study has poor visual outcome with 1/60 for both eyes after treatment. This patient came to us after 6 months of visual loss (late condition).

Conclusion

- The diagnosis approach to the patients with bilateral optic neuritis (symptoms and findings) is essential to define the management.
- Corticosteroid is still the first choice.
- Another combination of therapy probably needed based on the etiology and special circumstances.

Thank you